top of page

Free Biopharma Daily Stock Updates - 05/11/21


Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!


Covid Updates

$CERC FDA grants Fast Track Designation to CERC-002 for hospitalized patients with COVID-19. source

$BNTX and $PFE EUA expanded for COVID-19 vaccine to include individuals 12 to 15 years of age. source

$NVAX PREVENT-19 Phase 3 COVID-19 trial protocol updated; final data expected in second quarter of 2021. source

$CLNN Phase 2 CNM-ZnAg COVID-19 trial initiated in Brazil. source

Pipeline Updates

$PSTX Presents P-BCMA-ALL01 data at ASGCT 2021. source

$CDAK exoAAV gene therapy platform presented at ASGCT 2021 shows potential as novel, targeted approaches. source

$AXLA EMMPACT Phase 2b clinical trial of AXA1125 begins patient screening at initial clinical sites. source

$VYGR Novel adeno-associated virus capsids demonstrate robust delivery across blood brain barrier. source

$AGTC Manufacturing process for rAAV2tYF-GRK1-RPGRco presented at ASGCT. source

$LRMR Phase 1 topline data for CTI-1601 reported. source

$XLRN Will present updates to PULSAR and SPECTRA trials at ATS0 211 and webcast on 5/19/21. source

$BEAM LNP-mRNA formulation for liver editing presented at ASGCT. source

$ORTX OTL-101 data to treat ADA-SCID published in New England Journal of Medicine. source

$LVTX LAVA-051 will enter clinic in Phase 1/2a study in first half of 2021. source

$PMVP Will participate in Bank of America Healthcare Conference on May 13, 2021. source

$AUPH Company sponsored program initiated to help patients living with lupus and lupus nephritis. source

$MCRB Key data on C. Difficile infection therapeutics to be presented at DDW meeting May 21-23. source

$AVEO TIVO-3 Study data to be presented at ASCO meeting June 4-8. source

$DTIL In vivo genome editing program preclinical data presented at ASGCT. source

$MYOV Relugolix PDUFA dates still set for June 1 2021 and on track to submit regulatory filing for endometriosis in second quarter 2021. source

$APLT Phase 2 study of AT-007 in patients with SORD initiated. source

$IMRA IMR-687 Completed Phase 2a trial to present additional data at EHA June 9-17. source

Financial Updates

$PCRX Preliminary net product sales of EXPAREL and iovera in April 2021 were $42.1M and $1.5M respectively. source

$RAPT Cast as of first quarter was $98.4M and increase in clinical costs caused R&D expenses to increast to $13.8M. source

$ADMS First quarter revenue of $19.3M, 33% increase from 2020. source

bottom of page